Loading stock data…
APYX
$3.06-0.27 (-8.11%)
Market ClosedLast close May 1
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Apyx Medical Corporation in the Healthcare sector is trading at $3.06. The stock is currently 32% below its 52-week high of $4.50, remaining 5.0% below its 200-day moving average. Technical signals show oversold RSI of 15 and bearish MACD signal, explaining why APYX maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 15) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.06
Potential Upside
5%
Whystock Fair Value$3.21
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$160.21M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.54
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-131.62%
Volume
Today's trading volume
514,052
Recent News
How The Apyx Medical (APYX) Narrative Is Shifting With New Targets Guidance And Growth Drivers
Apyx Medical’s updated analyst narrative centers on a fresh US$6 price target, which sits alongside a fair value estimate of US$6.4 per share. Analysts linking this target to recent results point to sales that were in line, earnings that were ahead of prior expectations, and 2026 guidance that sits above earlier Street views, all while potential upside from the liposuction handpiece is not yet included. As you read on, you will see how bullish and cautious voices are shaping this evolving...
Is Agenus (AGEN) Outperforming Other Medical Stocks This Year?
Here is how Agenus (AGEN) and Apyx Medical (APYX) have performed compared to their sector so far this year.
Why The Apyx Medical (APYX) Story Is Shifting With New Guidance And GLP-1 Demand
Apyx Medical is back in focus after recent Street research highlighted a higher $6 price target, signaling a more constructive stance from some analysts. That shift is tied to updated views on operational progress, Ayon launch traction, and exposure to GLP-1 related demand trends, as well as discussion around international expansion and cost control efforts. In the sections that follow, you will see how these moving pieces shape the evolving analyst narrative and what to watch as new data...
Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year?
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to their sector so far this year.
Tilray Brands' Q3 Earnings on the Horizon: What's in The Offing?
TLRY heads into Q3 FY26 earnings with projected revenues up 10.9% and narrower losses, but margin pressure in cannabis and beverages clouds the outlook.